General Information of Drug Transporter (DT)
DT ID	DTD0537 Transporter Info
Gene Name	RALBP1
Protein Name	RalBP1-associated Eps domain-containing protein 2
Gene ID	10928
UniProt ID	Q8NFH8
Genetic Polymorphisms of DT (GPD)
Genetic Polymorphism	rs329007
Site of GPD	chr18:9522608 (GRCh38.p12)
GPD Type	SNP
Allele(s) in dbSNP	G>A / G>C
Minor Allele Frequency	G=0.2700/534 (Global)
Genotype GG	Click to Show/Hide the Full List of Affected Drugs:           4 Drugs in Total
Bevacizumab	N.A.	Alcohol Abuse	Genotype GG is associated with decreased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 1]
Fluorouracil	N.A.	Alcohol Abuse	Genotype GG is associated with decreased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 1]
Irinotecan	N.A.	Alcohol Abuse	Genotype GG is associated with decreased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 1]
Leucovorin	N.A.	Alcohol Abuse	Genotype GG is associated with decreased response to bevacizumab, fluorouracil, irinotecan and leucovorin in people with Colorectal Neoplasms as compared to genotypes AA + AG.		[ 1]
References
1	Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J. 2015 Feb;15(1):69-76.

If you find any error in data or bug in web service, please kindly report it to Dr. Li and Dr. Fu.